doi: 10.1161/01.HYP.0000018588.56950.7A
(Hypertension. 2002;39:1095.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF
From the Departments of Cardiovascular Research (A.K.O., R.Y., S.B., H.J.), Protein Engineering (B.L., A.M.deV.), and Clinical and Experimental Pharmacology (T.F.Z.), Genentech, Inc, South San Francisco, Calif; and Cardiovascular Research Lab, Providence Heart Institute, St Vincent Hospital (W.W., G.-W.H.), Portland, Ore.
Correspondence to Hongkui Jin, MD, Department of Cardiovascular Research, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080. E-mail hkj{at}gene.com
Abstract— Vascular endothelial growth factor (VEGF) exerts vasodilation-induced hypotension as a major side effect for treatment of ischemic diseases. VEGF has 2 receptor tyrosine kinases, KDR and Flt-1. Little is known about which receptor mediates VEGF-induced hypotension. To elucidate the role of each receptor in mediating hypotension, KDR-selective and Flt-1–selective mutants were used for in vitro and in vivo studies. The KDR-selective mutant induced vascular endothelial cell proliferation comparable to VEGF, whereas the Flt-1– selective mutant had no effect on proliferation. Intravenous injection of KDR-selective mutant, Flt-selective mutant, or VEGF caused a dose-related decrease in mean arterial pressure in conscious rats. The hypotensive response to KDR-selective mutant was significantly less than that to VEGF (P<0.01) but was greater than that to Flt-selective mutant (P<0.01). Similarly, VEGF and KDR-selective mutant induced more potent vasorelaxation than Flt-selective mutant or placenta growth factor that binds Flt-1 only (P<0.01), and the vasorelaxation to KDR-selective mutant was not significantly different at low concentrations but less than that to VEGF at high concentrations. The results indicate that the vasodilation and hypotensive effect of VEGF may involve both receptors, but KDR is the predominant receptor mediating this effect. Because KDR-selective mutant induced proliferation and angiogenesis similar to VEGF but was associated with 36% attenuation in hypotension, the data suggest that the KDR-selective mutant may represent an alternative treatment for ischemic diseases.
Key Words: growth substances • blood pressure • blood pressure determination • hypotension • vasodilation • receptors
This article has been cited by other articles:
 |
|
 |
|
  H. Suzuki, A. Ohkuchi, S. Matsubara, Y. Takei, M. Murakami, M. Shibuya, M. Suzuki, and Y. Sato Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice Hypertension, November 1, 2009; 54(5): 1129 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bhargava VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R1 - R5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lieb, R. Safa, E. J. Benjamin, V. Xanthakis, X. Yin, L. M. Sullivan, M. G. Larson, H. M. Smith, J. A. Vita, G. F. Mitchell, et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function Eur. Heart J., May 1, 2009; 30(9): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Curwen, H. L. Musgrove, J. Kendrew, G. H.P. Richmond, D. J. Ogilvie, and S. R. Wedge Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy Clin. Cancer Res., May 15, 2008; 14(10): 3124 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fujikawa, H. Shiraha, N. Ueda, N. Takaoka, Y. Nakanishi, N. Matsuo, S. Tanaka, S.-i. Nishina, M. Suzuki, A. Takaki, et al. Des-{gamma}-carboxyl Prothrombin-promoted Vascular Endothelial Cell Proliferation and Migration J. Biol. Chem., March 23, 2007; 282(12): 8741 - 8748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Abraldes, Y. Iwakiri, M. Loureiro-Silva, O. Haq, W. C. Sessa, and R. J. Groszmann Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state Am J Physiol Gastrointest Liver Physiol, May 1, 2006; 290(5): G980 - G987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S-C Wei, P-N Tsao, S-C Yu, C-T Shun, J-J Tsai-Wu, C H H Wu, Y-N Su, F-J Hsieh, and J-M Wong Placenta growth factor expression is correlated with survival of patients with colorectal cancer Gut, May 1, 2005; 54(5): 666 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Gordeuk, A. I. Sergueeva, G. Y. Miasnikova, D. Okhotin, Y. Voloshin, P. L. Choyke, J. A. Butman, K. Jedlickova, J. T. Prchal, and L. A. Polyakova Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors Blood, May 15, 2004; 103(10): 3924 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafpour, N. Huang, P. C. Neligan, C. R. Forrest, P. D. Addison, M. A. Moses, R. H. Levine, and C. Y. Pang Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H946 - H954. [Abstract] [Full Text] [PDF]
|
|